Dyne Therapeutics (DYN) Retained Earnings (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Retained Earnings of $2.4 billion for Q2 2026, up 37.24% year-over-year from $1.7 billion in Q2 2025, and up 0.67% quarter-over-quarter from $2.4 billion in Q1 2026.
Dyne Therapeutics (DYN) Retained Earnings (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Retained Earnings for 8 consecutive years, with $2.4 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings rose 37.24% year-over-year to $2.4 billion; the TTM figure through Jun 2026 stood at $2.4 billion (up 37.24% YoY), while the FY2025 annual figure was $2.4 billion, up 49.88% from the prior year.
- Retained Earnings climbed to $2.4 billion in Q2 2026 per DYN's latest filing, from $2.4 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $2.4 billion in Q2 2026 and bottomed at $601.4 million in Q1 2022.
- Historically, Retained Earnings has averaged $1.3 billion across 5 years, with a median of $1.4 billion in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings climbed 2.98% — and 2024, when it surged 118.26%.
- Dyne Therapeutics' Retained Earnings stood at $649.5 million in 2022, then increased by 11.44% to $723.8 million in 2023, then soared by 118.26% to $1.6 billion in 2024, then jumped by 49.88% to $2.4 billion in 2025, then advanced by 1.28% to $2.4 billion in 2026.
- Business Quant data shows DYN's Retained Earnings at $2.4 billion in Q2 2026, $2.4 billion in Q1 2026, and $2.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 2.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.40 Bn |
| Mar 31, 2026 | 2.38 Bn |
| Dec 31, 2025 | 2.37 Bn |
| Sep 30, 2025 | 1.98 Bn |
| Jun 30, 2025 | 1.75 Bn |
| Mar 31, 2025 | 1.73 Bn |
| Dec 31, 2024 | 1.58 Bn |
| Sep 30, 2024 | 1.57 Bn |
| Jun 30, 2024 | 1.54 Bn |
| Mar 31, 2024 | 1.18 Bn |
| Dec 31, 2023 | 723.80 Mn |
| Sep 30, 2023 | 717.92 Mn |
| Jun 30, 2023 | 712.59 Mn |
| Mar 31, 2023 | 682.89 Mn |
| Dec 31, 2022 | 649.50 Mn |
| Sep 30, 2022 | 608.47 Mn |
| Jun 30, 2022 | 604.57 Mn |
| Mar 31, 2022 | 601.44 Mn |
| Dec 31, 2021 | 596.93 Mn |
| Sep 30, 2021 | 590.83 Mn |